Anzeige
Mehr »
Login
Montag, 04.11.2024 Börsentäglich über 12.000 News von 674 internationalen Medien
Sagenhafte +10.000 % Gewinnchance mit Spezialisten für KI-Cybersecurity!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire
239 Leser
Artikel bewerten:
(1)

NOTICE OF TAKEOVER OFFER TO ACQUIRE SHARES OF NORDIC FIBREBOARD AS

1. Takeover offer and Offeror


NFB Pärnu Holdings OÜ (company registered in Estonia with registry code:
16786289 and registered address Pärnu mnt 18, 10141, Tallinn, Estonia,
"Offeror") in accordance with the Securities Market Act ("SMA") and other
applicable legal acts hereby makes a voluntary takeover offer for acquiring all
shares of Nordic Fibreboard AS ("NFB") not yet belonging to the Offeror or
persons related to it ("Offer"). The Offer is made based on this notice of
offer ("Notice of Offer") and the prospectus attached to it ("Prospectus",
together with the Notice of Offer, "Offer Documents"). 

The purpose of the Offer is to gain dominant influence over NFB by the Offeror.
The Offeror does not intend to apply for takeover of the remaining shares
either according to § 1821 of the SMA or provisions of chapter 291 of the
Estonian Commercial Code. Furthermore, as of the Date of the Prospectus (as
defined in the Prospectus) the Offeror does not intend to terminate the trading
with the shares of NFB at the Baltic Secondary List of Nasdaq Tallinn Stock
Exchange. 

The Offer relates to all Shares of NFB that are not held by the Offeror, the
100% (direct and indirect) owner of the Offeror Joakim Johan Helenius or Shares
held by Pärnu Holdings OÜ with respect to which, based on a shareholder
agreement, Joakim Johan Helenius holds sole decision-making powers ("Offer
Shares"). 

The Offeror makes the Offer to all shareholders of NFB except for the Offeror
itself, Joakim Johan Helenius and Pärnu Holdings OÜ to the extent that the NFB
Shares held by it are controlled by Joakim Johan Helenius. The Offeror wishes
to acquire all Offer Shares. 

 1. Target Company


The Target company of the Offer is Nordic Fibreboard AS a company registered in
Estonia with registry code 11421437 and registered address Rääma tn 31, 80044,
Pärnu town, Estonia. 

 1. Shares being the object of the Offer


The object of the Offer are registered ordinary shares "NORDIC FIBREBOARD
AKTSIA", ISIN code: EE3100092503 and total number of securities 4,499,061
shares ("Shares"). All Shares are freely transferrable and admitted to trading
at the Baltic Secondary List of Nasdaq Tallinn Stock Exchange (ticker symbol:
SKN1T). Each Shares gives the shareholder the right to participate in the
general meeting of shareholders of NFB, distribution of profit and liquidation
assets upon liquidation of NFB as well as other rights specified in applicable
regulations and articles of association of NFB. Each Share gives the
shareholder one vote at the general meeting of shareholder of NFB. 

 1. Shares belonging to the Offeror


The Offeror owns 1,750,135 NFB Shares that amounts to 38.9% of all NFB Shares.
In addition, the beneficial owner and holder of 100% shareholding (directly 50%
and indirectly 50%) of the Offeror, Joakim Johan Helenius owns directly 40,000
and indirectly 421,320 NFB Shares i.e. altogether 2,211,455 NFB Shares that
amounts to 49.15% of all NFB Shares. The Offeror is acting independently and
there are no persons acting in concert with the Offeror (within the meaning of
§ 168 of SMA). 

 1. Number of Shares being acquired and purchase price


In the context of the Offer, the Offeror wishes to acquire, and the Offer is
made to acquire in total 2,287,606 Shares. Thus, all Shares not belonging to
the Offeror or persons related to it are the object of the Offer. Such Shares
amount to 50.85% of all the Shares. The Offer is made at a price of EUR 0.944
per Share. The minimum number of Shares is not determined i.e. the Offeror
wishes to acquire all Offer Shares that are offered for sale to the Offeror. 

 1. Procedure for settlement


Shares sold by the Selling Shareholders (as defined in the Prospectus) to the
Offeror during the Offer shall be transferred from each Selling Shareholder to
the Offeror simultaneously with the transferal of the purchase price equivalent
to the amount of sold Shares to the bank account of the Selling Shareholder on
27 May 2024 ("Settlement Day"). 

 1. Offer period


The deadline of the Offer is 23 May 2024 at 16:00 Tallinn time. NFB
shareholders that wish to offer Shares to the Offeror during the Offering, can
do so according to the procedure specified in the Prospectus from the date of
publication of this Notice of Offer i.e. from 25 April 2024 at 10:00 Tallinn
time until the deadline of the Offer on 23 May 2024 at 16:00 Tallinn time. 

 1. Approval of the Estonian Financial Supervision and Resolution Authority 


The Offer Documents were submitted to the Financial Supervision and Resolution
Authority for approval on 4 April 2024. The Financial Supervision and
Resolution Authority approved the Offer Documents on 24 April 2024. 

 1. Places of publication and distribution of Offer Documents 


The Prospectus is electronically published at:

 -- Nasdaq Tallinn Stock Exchange website (

www.nasdaqbaltic.com/

);

 -- Financial Supervision and Resolution Authority website (

www.fi.ee

); and

 -- NFB website (

https://group.nordicfibreboard.com/et/investor/

). 


The Notice of Offer is electronically published at:

 -- Nasdaq Tallinn Stock Exchange website (

www.nasdaqbaltic.com/

); and

 -- NFB website (

https://group.nordicfibreboard.com/et/investor/

). 


The Notice of Offer is published at Estonian newspaper Õhtuleht on 26 April
2024. 

Anyone wishing to obtain the hard copy of the Prospectus and Notice of Offer
should inform the Offeror vie e-mail at legal@trigoncapital.com, phone: +372
667 9200, or mail: Pärnu mnt 18, 10141, Tallinn, Estonia. 

 1. Important information 


The Offer is being made in accordance with the laws of the Republic of Estonia
and will not be subject to any review or approval by any foreign regulatory
authority. The Offer is not being made to persons whose participation in the
Offer requires an additional offer document to be prepared, a registration
effected or that any other measures would be taken in addition to those
required under the laws of the Republic of Estonia. In the event of any
inconsistency between the contents of the Prospectus and any other document or
release, the provisions of the Prospectus in the Estonian language shall
prevail. 

This Notice of Offer is not for release or distribution, directly or
indirectly, in or into any jurisdiction where to do so would be unlawful or to
persons or jurisdictions who are subject to financial sanctions imposed by
competent authorities. Persons receiving this document, or any other related
documents (including custodians, nominees and trustees) must observe these
restrictions and must not send or distribute this document in or into the
relevant jurisdictions or to relevant persons. 

Neither this Notice of Offer nor any other information supplied in connection
with the Offer should be considered as a recommendation by either Offeror or by
any other person to any recipient of this Notice of Offer (including any other
information supplied in connection with the Offer) to sell any NFB Shares. Each
person who contemplates selling any Shares should make its own independent
investigation of the financial condition and affairs of NFB and its
subsidiaries, the Offerors plans after takeover of NFB Shares in case of
different scenarios and give its own appraisal to the Offer. 

Unless otherwise specified in the Offer Documents, all information contained in
this Notice of Offer is presented as of the Date of the Prospectus, i.e. as of
4 April 2024. 





Annex - Offer Prospectus

Attachment:
https://cns.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=1215433
© 2024 GlobeNewswire
Tenbagger-Chance mit der nächsten BioNTech

Erinnern Sie sich, als Moderna und BioNTech von unbekannten Unternehmen zu globalen Marktführern wurden und frühzeitige Investoren reich belohnt haben?

Die Branche steht vor einem erneuten Innovationsschub – von bahnbrechenden Medikamenten bis hin zu revolutionären Therapien.

Warum sollten Sie dabei sein?

Sie sollten jetzt in Biotech-Aktien einsteigen, weil wir am Beginn einer neuen Ära der medizinischen Innovation stehen könnten! Gen- und Zelltherapien, personalisierte Medizin und bahnbrechende Technologien könnten das Gesundheitswesen revolutionieren – und die Aktienkurse in die Höhe schießen lassen.

Die nächste Erfolgsgeschichte im Biotechbereich warten nur darauf, entdeckt zu werden. Wer jetzt investiert, hat die Chance, von gigantischen Durchbrüchen und enormen Renditen zu profitieren. Warten Sie nicht, bis es zu spät ist - der nächste Biotech-Superstar könnte morgen schon durchstarten!

Verpassen Sie nicht diese Chance!

Fordern Sie sofort unseren brandneuen Biotech-Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien das riesige Potenzial haben, Ihren finanziellen Erfolg zu sichern. Dieser Report ist komplett kostenlos und zeigt Ihnen zukunftsträchtige Investments im Biotech-Sektor.

Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.